Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | COMT | P21964 | 3/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL456256 | 0.84 | DAO (0.32) | DAO | |
| SCHEMBL7470990 | 0.82 | AURKA (0.32) | DAOKMT2AADRA2AADRA2C | |
| SCHEMBL18966703 | 0.82 | SLC6A2 (0.42) | DAOADRA2AADRA2CCYP2D6 | |
| SCHEMBL10537577 | 0.82 | DAO (0.32) | DAO | |
| SCHEMBL17448253 | 0.79 | TAAR1 (0.35) | DAOTAAR1ADRA2AADRA2CCYP2D6 | |
| SCHEMBL270836 | 0.77 | SLC6A2 (0.44) | KMT2A | |
| SCHEMBL5865581 | 0.77 | KMT2A (0.47) | KMT2A | |
| SCHEMBL9290918 | 0.76 | DAO (0.53) | DAOCOMTTYRKMT2AADRA2A | |
| SCHEMBL11293327 | 0.76 | KDM4E (0.47) | KMT2AADRA2AADRA2CCYP2D6LMNA | |
| SCHEMBL7467600 | 0.76 | L3MBTL1 (0.46) | KMT2ALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-15 | — | — | US | disclosed |
| US-20170157135-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-08 | — | — | US | disclosed |
| US-20170158636-A1 | FUNCTIONALISED AND SUBSTITUTED CARBAZOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-08 | — | — | US | disclosed |
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-01 | — | — | US | disclosed |
| WO-2016008010-A1 | FUNCTIONALISED AND SUBSTITUTED CARBAZOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016008011-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2016-01-21 | — | — | WO | disclosed |
| EP-1246623-A4 | COMPOUNDS SPECIFIC TO ADENOSINE A1, A2A, AND A3 RECEPTOR AND USES THEREOF | OSI PHARM INC (US) | 2003-05-14 | — | — | EP | disclosed |
| EP-1246623-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1, A2A, AND A3 RECEPTOR AND USES THEREOF | OSI Pharmaceuticals, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001039777-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1 A2A, AND A3 RECEPTORS AND USES THEREOF | OSI PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| EP-0611301-A1 | CHELATOR COMPOSITIONS COMPRISING OXIME COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 1994-08-24 | — | — | EP | disclosed |
| EP-0611301-A4 | CHELATOR COMPOSITIONS COMPRISING OXIME COMPOUNDS. | PROCTER & GAMBLE (US) | 1993-03-01 | — | — | EP | disclosed |
| WO-1991016034-A1 | CHELATOR COMPOSITIONS COMPRISING OXIME COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158636-A1 | FUNCTIONALISED AND SUBSTITUTED CARBAZOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | DAO 3155/4885COMT 1551/4885TYR 408/4885 |
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | DAO 2339/4885COMT 303/4885TYR 82/4885 |
| US-20170157135-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | DAO 2339/4885COMT 303/4885TYR 82/4885 |
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | DAO 2132/4885COMT 269/4885TYR 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.